Superworth

Avantor price to free cash flow AVTR

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Nov 2, 2026
23.2×
7-year median
20.7×
Against its 7-year history
70th
percentile: 0 is its lowest day, 100 its highest
7-year range
10.2× to 29.6×
Peer median
25.6×

Avantor's price to free cash flow is 23.2× as of Nov 2, 2026.

That is above its 7-year median of 20.7×, higher than on 70% of days in the last 7 years.

Over that time it ranged from 10.2× in Mar 2026 to 29.6× in Dec 2021.

The median for 10 diagnostics and research stocks of a similar size is 25.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far23.2×10.2×25.7×
202514.9×12.3×20.3×
202419.5×18.9×26.6×
202322.2×16.9×23.8×
202217.8×16.2×26.5×
202129.6×18.3×29.6×
202024.8×20.1×24.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first, today.

CompanyPrice to free cash flow
AVTRAvantor23.2×
BIOBio-Rad Laboratories27.7×
CAICaris Life Sciences73.2×
RVTYRevvity30.3×
LNTHLantheus16.9×
MEDPMedpace25.6×
BLLNBillionToOne157×
CDNACareDxn/m
DGXQuest Diagnostics20.0×
VCYTVeracyte23.7×
LHLabcorp25.0×
Peer median25.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Avantor

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.